EMEA-001370-PIP02-13 - paediatric investigation plan

Herpes simplex 1 virus thymidine kinase and truncated low affinity nerve growth factor receptor transfected donor lymphocytes

Key facts

• Active Substance:
  Herpes simplex 1 virus thymidine kinase and truncated low affinity nerve growth factor receptor transfected donor lymphocytes
• Therapeutic area:
  Oncology
• Decision number:
  P/0057/2014
• PIP number:
  EMEA-001370-PIP02-13
• Pharmaceutical form(s):
  Cell suspension for infusion
• Condition(s) / indication(s):
  Adjunctive treatment in haematopoietic cell transplantation
• Route(s) of administration:
  Intravenous use
• Contact for public enquiries:

  MolMed S.p.A.

  Italy ; E-mail: [e-mail] ; Tel. [phone] ; Fax [phone]

• Decision type:
  P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
• Decision date:
  06/03/2014

Decision

P/0057/2014: European Medicines Agency decision of 6 March 2014 on the agreement of a paediatric investigation plan and on the granting of a deferral for herpes simplex 1 virus thymidine kinase and truncated low affinity...

AdoptedReference Number: EMA/111582/2014